CA2641318C - Molecules for the treatment of lung disease involving an autoimmune reaction to connective tissue found in the lung - Google Patents

Molecules for the treatment of lung disease involving an autoimmune reaction to connective tissue found in the lung Download PDF

Info

Publication number
CA2641318C
CA2641318C CA2641318A CA2641318A CA2641318C CA 2641318 C CA2641318 C CA 2641318C CA 2641318 A CA2641318 A CA 2641318A CA 2641318 A CA2641318 A CA 2641318A CA 2641318 C CA2641318 C CA 2641318C
Authority
CA
Canada
Prior art keywords
collagen
col
lung
type
transplantation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2641318A
Other languages
English (en)
French (fr)
Other versions
CA2641318A1 (en
Inventor
David S. Wilkes
Michael J. Klemsz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Indiana University Research and Technology Corp
Original Assignee
Indiana University Research and Technology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indiana University Research and Technology Corp filed Critical Indiana University Research and Technology Corp
Priority to CA2965211A priority Critical patent/CA2965211C/en
Publication of CA2641318A1 publication Critical patent/CA2641318A1/en
Application granted granted Critical
Publication of CA2641318C publication Critical patent/CA2641318C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Rehabilitation Therapy (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
CA2641318A 2006-01-13 2007-01-13 Molecules for the treatment of lung disease involving an autoimmune reaction to connective tissue found in the lung Active CA2641318C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2965211A CA2965211C (en) 2006-01-13 2007-01-13 Type v collagen-related molecules for the treatment of lung disease involving autoimmunity to type v collagen _________________________________________

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75919506P 2006-01-13 2006-01-13
US60/759,195 2006-01-13
PCT/US2007/060533 WO2007120947A1 (en) 2006-01-13 2007-01-13 Molecules for the treatment of lung disease involving an immune reaction to connective tissue found in the lung

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2965211A Division CA2965211C (en) 2006-01-13 2007-01-13 Type v collagen-related molecules for the treatment of lung disease involving autoimmunity to type v collagen _________________________________________

Publications (2)

Publication Number Publication Date
CA2641318A1 CA2641318A1 (en) 2007-10-25
CA2641318C true CA2641318C (en) 2017-06-20

Family

ID=38609836

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2641318A Active CA2641318C (en) 2006-01-13 2007-01-13 Molecules for the treatment of lung disease involving an autoimmune reaction to connective tissue found in the lung
CA2965211A Active CA2965211C (en) 2006-01-13 2007-01-13 Type v collagen-related molecules for the treatment of lung disease involving autoimmunity to type v collagen _________________________________________

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2965211A Active CA2965211C (en) 2006-01-13 2007-01-13 Type v collagen-related molecules for the treatment of lung disease involving autoimmunity to type v collagen _________________________________________

Country Status (8)

Country Link
US (3) US7759075B2 (https=)
EP (2) EP1977234B1 (https=)
JP (2) JP5030973B2 (https=)
CN (1) CN101375157B (https=)
AU (1) AU2007238533C1 (https=)
BR (1) BRPI0706575B8 (https=)
CA (2) CA2641318C (https=)
WO (1) WO2007120947A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2641318C (en) * 2006-01-13 2017-06-20 Indiana University Research & Technology Corporation Molecules for the treatment of lung disease involving an autoimmune reaction to connective tissue found in the lung
EP3037096B1 (en) * 2006-11-28 2019-05-01 University Of Southern California Method for promoting wound healing
KR20110135938A (ko) * 2009-02-13 2011-12-20 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 매트릭스 메탈로프로테이나제(ｍｍｐ)2 및 ｍｍｐ9를 억제하기 위한 화합물 및 방법
CN107243076A (zh) * 2009-04-22 2017-10-13 印第安那大学科技研究公司 用于治疗慢性阻塞性肺病和哮喘的组合物和方法
HUE052213T2 (hu) 2009-11-06 2021-04-28 Univ Leland Stanford Junior Grafitkilökõdés nem invazív diagnosztizálása szervátültetett betegekben
AU2012262154B2 (en) * 2011-05-31 2016-08-04 Idexx Laboratories, Inc. Detection of degradation products of feline NT-proBNP
EP3725892A1 (en) * 2012-03-27 2020-10-21 F. Hoffmann-La Roche AG Methods of prognosing, diagnosing and treating idiopathic pulmonary fibrosis
JP6058354B2 (ja) * 2012-11-02 2017-01-11 東芝メディカルシステムズ株式会社 画像処理装置及び画像処理方法
JP6312054B2 (ja) * 2013-11-06 2018-04-18 学校法人日本大学 間質性肺炎のバイオマーカー
US20170082619A1 (en) 2015-09-23 2017-03-23 One Lambda, Inc. Methods of Detecting Alloantibodies Using HLA and Non-HLA Antigens

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444879A (en) * 1981-01-29 1984-04-24 Science Research Center, Inc. Immunoassay with article having support film and immunological counterpart of analyte
DE69121844T2 (de) * 1990-11-20 1997-01-23 Behringwerke Ag Immunotest für Cyclosporin
US6911220B1 (en) * 1992-02-19 2005-06-28 The General Hospital Corporation Allogeneic and xenogeneic transplantation
JP2702354B2 (ja) * 1992-05-11 1998-01-21 帝人株式会社 血中の肺組織障害マーカー
US5778875A (en) * 1996-05-06 1998-07-14 U.S. Divers Co., Inc. First stage regulator and rotatable in-line valve
AUPO026596A0 (en) * 1996-06-05 1996-06-27 Biomolecular Research Institute Limited Viral peptide
US5962025A (en) * 1996-07-16 1999-10-05 The University Of Tennessee Research Corporation Method for treatment of systemic sclerosis and related fibrotic diseases
US5990274A (en) * 1997-11-25 1999-11-23 Dade Behring Inc. Cyclosporine derivatives and uses thereof
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
AU2001230531A1 (en) * 2000-01-31 2001-08-14 Asahi Kasei Kabushiki Kaisha Antibody for detecting chlamydia pneumoniae
US7348005B2 (en) * 2000-03-15 2008-03-25 Advanced Research And Technology Institute Oral tolerance induction by collagen to prevent allograft rejection
CA2399028A1 (en) * 2000-03-23 2001-09-27 Akzo Nobel N.V. Use of mia in immunotherapy
JP2002220343A (ja) * 2001-01-26 2002-08-09 Toray Ind Inc びまん性肺疾患延命剤
JP2007532883A (ja) * 2004-04-08 2007-11-15 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 組織サンプルにおけるコラーゲンの免疫組織化学的検出方法
AU2006315428B2 (en) 2005-11-16 2011-12-01 The University Of Tennessee Research Foundation Methods of treating fibrosing diseases by induction of immune tolerance
CA2641318C (en) 2006-01-13 2017-06-20 Indiana University Research & Technology Corporation Molecules for the treatment of lung disease involving an autoimmune reaction to connective tissue found in the lung

Also Published As

Publication number Publication date
EP2672266B1 (en) 2018-08-01
AU2007238533B2 (en) 2012-09-20
EP1977234A4 (en) 2009-06-03
BRPI0706575A2 (pt) 2011-04-05
JP2012108137A (ja) 2012-06-07
US7759075B2 (en) 2010-07-20
US20090017013A1 (en) 2009-01-15
US20110183356A1 (en) 2011-07-28
US20110020838A1 (en) 2011-01-27
AU2007238533C1 (en) 2013-08-15
HK1126861A1 (en) 2009-09-11
EP2672266A3 (en) 2014-02-05
BRPI0706575B8 (pt) 2021-05-25
US8039225B2 (en) 2011-10-18
BRPI0706575B1 (pt) 2018-12-11
WO2007120947A1 (en) 2007-10-25
EP1977234A1 (en) 2008-10-08
JP2009524023A (ja) 2009-06-25
US7939281B2 (en) 2011-05-10
CA2965211A1 (en) 2007-10-25
JP5936349B2 (ja) 2016-06-22
AU2007238533A1 (en) 2007-10-25
CN101375157B (zh) 2015-06-17
CA2965211C (en) 2020-06-30
CN101375157A (zh) 2009-02-25
JP5030973B2 (ja) 2012-09-19
CA2641318A1 (en) 2007-10-25
EP1977234B1 (en) 2015-11-04
EP2672266A2 (en) 2013-12-11

Similar Documents

Publication Publication Date Title
US8039225B2 (en) Method to identify patients at risk for lung transplant rejection
Ciubotariu et al. Persistent allopeptide reactivity and epitope spreading in chronic rejection of organ allografts.
EP1509771A2 (en) Systems and methods for identifying organ transplant risk
RU2723554C2 (ru) Диагностика инфекционного заболевания дыхательных путей с использованием образцов крови
US8563259B2 (en) Complement-mediated thrombophilic assay
US9005982B2 (en) Biomarkers associated with autoimmune diseases of the lung
Dauchel et al. Local and systemic activation of the whole complement cascade in human leukocytoclastic cutaneous vasculitis; C3d, g and terminal complement complex as sensitive markers
Latorre-Rodríguez et al. Noninvasive biomarkers for the detection of GERD-induced pulmonary injury
CN102458446B (zh) 用于治疗慢性阻塞性肺病和哮喘的组合物和方法
HK1126861B (en) Molecules for the treatment of lung disease involving an immune reaction to connective tissue found in the lung
US7348005B2 (en) Oral tolerance induction by collagen to prevent allograft rejection
Aziz et al. Immunobiology, Diagnosis, and Treatment of Rejection
US20240067717A1 (en) Diagnosis and treatment of primary graft dysfunction following lung transplant
WO2019077143A1 (en) METHODS AND COMPOSITIONS FOR PREDICTING AND PRECOCUALLY DIAGNOSING A CHRONIC ACTIVE FORM OF ABMR WITH GRAFT GLOMERULOPATHY AND RENAL TRANSPLANT LOSS
O'Sullivan Goodpasture's syndrome: An example of an autoimmune process in the clinical and diagnostic setting
Ratkay Investigation of an adjuvant-enhanced model of murine arthritis and its therapeutic application
Backman et al. Chronic cutaneous bacterial hypersensitivity
JP2008061622A (ja) 造血幹細胞移植療法の施行患者の病態把握方法

Legal Events

Date Code Title Description
EEER Examination request
MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 18TH ANNIV.) - STANDARD

Year of fee payment: 18

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250103

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250103